SCHEMBL6406728

SCHEMBL6406728

O=c1ccnc2ccccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
NPC1 O15118 3/20 0.47
POLB P06746 2/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 3/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46
ACHE P22303 1/20 0.46
CYP1A2 P05177 1/20 0.45
PDGFRB P09619 2/20 0.44
PDGFRA P16234 2/20 0.44
MGAM O43451 1/20 0.44
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL28157695 0.75 ALDH1A1 (0.85) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL137291 0.74 ALDH1A1 (0.94) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL27611581 0.72 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL27594824 0.72 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL11879891 0.72 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL27457480 0.72 ALDH1A1 (0.90) ALDH1A1NPC1POLBRAB9AMAPT
Acridine SCHEMBL463236 0.71 ALDH1A1 (0.77) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL29120681 0.71 ALDH1A1 (0.77) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL29822171 0.71 ALDH1A1 (1.00) ALDH1A1NPC1POLBRAB9AMAPT
Quinoline SCHEMBL29349552 0.71 ALDH1A1 (1.00) ALDH1A1NPC1POLBRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875877-B2 Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides LI JINGLIN JAMES T (US) 2005-04-05 US disclosed
EP-1331225-A1 Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides G.D. SEARLE & CO. (US) 2003-07-30 EP disclosed
EP-1042314-B1 METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES SEARLE & CO (US) 2003-03-19 EP disclosed
US-20020188119-A1 Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides LI JINGLIN (US) 2002-12-12 US disclosed
US-6369220-B1 OXIDIZING AN ARYL-3-HYDROXYPROPYLSULFIDE; OXIDIZING 3-HYDROXY GROUP INTO ARYL-3-PROPANALSULFOXIDE; CYCLIZATION G.D. SEARLE, LLC 2002-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188119-A1 Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides TST, THOP1, TH ALDH1A1 767/4885NPC1 4462/4885POLB 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.